Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients-Reference-Cited by-同舟云学术

Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients

Published:2021-08-17 Issue:9 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Tian Xueke¹²,Zhang Congmin¹²,Qin Zifei¹²,Wang Dao³,Yang Jing¹²^ORCID,Zhang Xiaojian¹²

Affiliation:

1. Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

2. Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China

3. Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

Abstract

Voriconazole (VRC), a first-line agent for the treatment of invasive fungal infections, is mainly metabolized by human cytochrome P450 (CYP) 2C19. In this study, a retrospective analysis was performed to investigate the key factors that influence the plasma trough concentration ( C min ) of VRC, and an appropriate dosing regimen for pediatric patients was drafted subsequently.

Funder

MOST | National Key Research and Development Program of China

National Natural Science Foundation of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00207-21

Reference32 articles.

1. Epidemiology of Invasive Fungal Disease in Children

2. Voriconazole Resistance and Mortality in Invasive Aspergillosis: A Multicenter Retrospective Cohort Study